^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
TmEGFR/IL13Rα2 01 CAR-T
i
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Gilead, University of Pennsylvania
Drug class:
EGFR-targeted CAR-T immunotherapy, IL-13-targeted CAR-T immunotherapy
Related drugs:
2years
CART-EGFR-IL13Ra2 in EGFR Amplified Recurrent GBM (clinicaltrials.gov)
P1, N=18, Recruiting, University of Pennsylvania | Not yet recruiting --> Recruiting
Enrollment open
|
EGFR (Epidermal growth factor receptor)
|
EGFR amplification • EGFR wild-type • IDH wild-type
|
TmEGFR/IL13Rα2 01 CAR-T
over2years
CART-EGFR-IL13Ra2 in EGFR Amplified Recurrent GBM (clinicaltrials.gov)
P1, N=18, Not yet recruiting, University of Pennsylvania | Initiation date: Jun 2022 --> Mar 2023
Trial initiation date
|
EGFR (Epidermal growth factor receptor)
|
EGFR amplification • EGFR wild-type • IDH wild-type
|
cyclophosphamide • fludarabine IV • TmEGFR/IL13Rα2 01 CAR-T
3years
CART-EGFR-IL13Ra2 in EGFR Amplified Recurrent GBM (clinicaltrials.gov)
P1, N=18, Not yet recruiting, University of Pennsylvania | Initiation date: Dec 2021 --> Jun 2022
Clinical • Trial initiation date
|
EGFR (Epidermal growth factor receptor)
|
EGFR amplification • EGFR wild-type • IDH wild-type
|
cyclophosphamide • fludarabine IV • TmEGFR/IL13Rα2 01 CAR-T
3years
CART-EGFR-IL13Ra2 in EGFR Amplified Recurrent GBM (clinicaltrials.gov)
P1, N=18, Not yet recruiting, University of Pennsylvania
Clinical • New P1 trial
|
EGFR (Epidermal growth factor receptor)
|
EGFR amplification • EGFR wild-type • IDH wild-type
|
cyclophosphamide • fludarabine IV • TmEGFR/IL13Rα2 01 CAR-T
Share via
